Children and teenagers with type 1 diabetes are more likely to have eating disorders.

The investigational sodium/glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin (Merck), being developed to improve glycemic control in adults with type 2 diabetes, met the primary outcomes in two yearlong phase 3 trials, VERTIS SU and VERTIS SITA2.

First Continuous Glucose Monitor that doesn’t require routine finger pricks.

Visit diabetes.org/hurricanerelief for information on the latest shelter locations; information for people with diabetes and caregivers; information for emergency responders and relief personnel; how to donate unexpired and unopened diabetes supplies; and federal and state assistance resources.

The pinprick or sharp sensation test is acknowledged and recommended by the ADA as a useful and sensitive method of testing for Loss Of Protective Sensation and predicting serious complications associated with diabetes. Medipin is a unique single use cutaneous pinprick testing device. Its patented precision technology has been designed to enhance patient pinprick sensation response.

Acanthosis nigricans presents as a brown to black pigmentation usually seen in the neck or armpit areas. In relation to diabetes, this may indicate: A) granuloma annulare B) diabetic dermopathy C) type 1 diabetes D) insulin resistance Follow the link to see the correct answer.

Fresh off the Larry H. Miller Tour of Utah and with little time to recover, Team Novo Nordisk tackled the high-altitude Colorado Classic. Team Novo Nordisk's squad included three neo-pros (new professionals), one stagiaire (basically an intern looking for a contract) and two veteran riders, so a very young and fairly inexperienced squad.

Only 6% of PCP’s were able to identify 11 prediabetes risk factors (there are actually 13) that would prompt them to screen patients under the ADA guidelines according to a new study. Are you any better?

CANVAS Program results confirm cardiovascular benefits are SGLT-2 Inhibitor Class effect.

Why Google, Apple, and Amazon entering the diabetes market is the real big story from ADA.